Clinical Trials Sponsored by Wave+Life+Sciences+Ltd.

Total 124 results

Wave Life Sciences Ltd.

Recruiting

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (RestorAATion-1)

Alpha-1 Antitrypsin Deficiency

United Kingdom
Wave Life Sciences Ltd.

Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

ALS | FTD

Netherlands, United Kingdom
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1)

Huntington's Disease

Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Wave Life Sciences Ltd.

Completed

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, United Kingdom, France, United States, Italy, Canada, Netherlands
Wave Life Sciences Ltd.

Recruiting

Study of WVE-003 in Patients With Huntington's Disease

Huntington Disease

Canada, Spain, Australia, Denmark, Netherlands, Poland, United Kingdom, France, Germany, Italy
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (PRECISION-HD2)

Huntington's Disease

United States, Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
Wave Life Sciences Ltd.

Active, not recruiting

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Duchenne Muscular Dystrophy

Jordan, United Kingdom
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Nimble Science Ltd.
IGY Life Sciences

Recruiting

Evaluation of the Microbiome in Multiple Sclerosis

Multiple Sclerosis

Canada
Tiziana Life Sciences LTD

Recruiting

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

United States
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
Tiziana Life Sciences LTD

Withdrawn

In-patient COVID-19 Study of Intranasal Foralumab

Covid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
Tiziana Life Sciences LTD

Withdrawn

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

NAFLD | NASH - Nonalcoholic Steatohepatitis | T2DM (Type 2 Diabetes Mellitus)
Avacta Life Sciences Ltd

Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Soft Tissue Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer | Oesophageal Cancer | Cancer of Unknown Primary Site

United States, United Kingdom
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD

Completed

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Israel, Greece, Italy
CANbridge Life Sciences Ltd.

Completed

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Multiforme

Taiwan
CANbridge Life Sciences Ltd.

Unknown

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Glioblastoma
Clinical Life Sciences Ltd.

Completed

Effect of Plant Stanol Esters on Blood Lipids

Elevated Blood Lipids

Finland
Tiziana Life Sciences LTD

Not yet recruiting

Milciclib in Combination With Gemcitabine in Advanced NSCLC

NSCLC
Tiziana Life Sciences LTD

Terminated

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Malignant Thymoma

United States, Italy
Tiziana Life Sciences LTD

Terminated

Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Thymic Carcinoma

United States, France, Italy
CANbridge Life Sciences Ltd.

Unknown

To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

GBM
Meril Life Sciences Pvt. Ltd.

Not yet recruiting

Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions (MeRethonRCT)

Coronary Artery Disease
Meril Life Sciences Pvt. Ltd.

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV (LANDMARK)

Aortic Valve Stenosis

Sweden, Hungary, France, Belarus, Croatia, Germany, Netherlands, New Zealand, Poland, Portugal, Slovakia, Slovenia, Spain, Italy, Brazil, Estonia, Greece
Meril Life Sciences Pvt. Ltd.

Unknown

A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus)

Angina Pectoris

Jordan, Hungary, Malaysia, Netherlands
Ivy Life Sciences, Co., Ltd

Completed

Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer

Lung Cancer | Liver Cancer | NSCLC Stage IV | Hepatocellular Carcinoma by BCLC Stage | NSCLC Stage IIIB
Meril Life Sciences Pvt. Ltd.

Completed

An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study. (meriT-2)

Coronary Artery Disease

India
Meril Life Sciences Pvt. Ltd.

Recruiting

Myval Global Study of Myval™ THV Series Implanted in Patients With Native Severe Aortic Valve Stenosis.

Aortic Valve Stenosis

Slovenia, Spain, Turkey, Italy, Netherlands, Estonia, Poland
Meril Life Sciences Pvt. Ltd.

Unknown

Clinical Study Comparing Single Long BioMimeTM Morph Coronary Stent System vs. Two Overlapping Xience Family Coronary Stent Systems in the Treatment of Patients With Long de Novo Lesions. (Morph RCT-1)

Coronary Artery Disease
Meril Life Sciences Pvt. Ltd.

Unknown

Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (MeRes-1Extend)

Coronary Artery Disease

Malaysia, Brazil, Indonesia, Macedonia, The Former Yugoslav Republic of
Meril Life Sciences Pvt. Ltd.

Not yet recruiting

Freedom® Total Knee System for Treatment of Osteoarthritis, Rheumatoid Arthritis or Post-traumatic Arthritis (Freedom®450)

Rheumatoid Arthritis | Knee Osteoarthritis | Post-traumatic Osteoarthritis
Meril Life Sciences Pvt. Ltd.

Not yet recruiting

Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease. (MeReS100-China)

Coronary Artery Disease
Meril Life Sciences Pvt. Ltd.

Unknown

BioMime Vs. Xience Randomised Control Clinical Study (meriT-V)

Coronary Artery Disease

United Kingdom, Brazil, Spain, Macedonia, The Former Yugoslav Republic of, Belgium, Czechia, Latvia, Netherlands, Poland
Clinical Life Sciences Ltd.
Fazer

Completed

Measurement of Glycaemic Responses of Bakery and Confectionery Products (GIFA)

Healthy

Finland
Brain Health Scotland Life Sciences Ltd

Recruiting

IONA Longitudinal Cohort Study (IONA LCS)

Dementia | Alzheimer Disease

United Kingdom
CARE Pharma Shanghai Ltd.

Completed

Natural History Study of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria of High-risk Hemolysis in China

Paroxysmal Nocturnal Hemoglobinuria, Natural History Study

China
CARE Pharma Shanghai Ltd.

Recruiting

A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Hemolysis | PNH

China
CARE Pharma Shanghai Ltd.

Completed

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

PNH

Singapore
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Study of RBD1016 in CHB Participants

Chronic Hepatitis b

Sweden
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis b

China
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Healthy Volunteers

Australia
Hangzhou Nuochi Life Science Co., Ltd.

Completed

Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram

Healthy People

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Hyperlipemia

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Healthy Volunteers

Australia
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Health Volunteer

Australia

Clinical Trials Sponsored by Wave+Life+Sciences+Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations